Sources

10 Total Sources

Pfizer’s Sigvotatug Vedotin Fails Lung Cancer Trial After $43 Billion Seagen Bet

Left29%

Center71%

Pfizer's Sigvotatug Vedotin Lung Cancer Drug Fails Clinical Trial

pharmaphorum18h ago

Pfizer's Seagen-derived ADC pipeline suffers a setback | pharmaphorum

Fierce Biotech1d ago

Pfizer's first new ADC from Seagen acquisition fails phase 3 NSCLC trial | Fierce Biotech

linkedin12h ago

misses #overall #survival #endpoint #nsclc #phase3 #adc #pfizer #nsclc # lungcancer #adc #antibodydrugconjugates #oncology #cancerresearch #immunotherapy #biotech #drugdevelopment | Jack Shuang Hou

The Japan Times18h ago

Pfizer's lung cancer drug trial fails to boost survival - The Japan Times

Investing.com Canada1d ago

Pfizer lung cancer drug trial fails primary endpoint By Investing.com

Bloomberg5h ago

Pfizer's Sigvotatug Vedotin Lung Cancer Drug Trial Fails to Boost Survival

Pfizer's experimental drug misses main goal of lung cancer trial | Reuters

en.oninvest.com15h ago

Pfizer's lung cancer drug trial has failed. What will happen to the stock? – Oninvest

Pfizer's Sigvotatug Vedotin Misses Primary Overall Survival Endpoint In Phase 3 NSCLC Study